1 hot UK growth stock I’m buying right now

I’ve more than doubled my money on this UK growth stock. But with a 948% boost to earnings, I think Hvivo is an even better buy now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s not often I put thousands of pounds into one UK growth stock. But my research has led me to handpick this one opportunity, and I’m buying more.

With an expected 948% increase in earnings in the next 12 months, I think Hvivo (LSE:HVO) could be a winner for me.

Hvivo shares shot up to a peak of 38p amid the global investor frenzy around Covid stocks. Today the shares are worth half that, at around 20p. So why am I adding to my position?

I first noticed Hvivo during the pandemic when its market cap was a tiny £30m. Today the company is worth around £135m.

It runs human challenge clinical trials for flu and other respiratory illnesses. its scientists expose healthy volunteers to infection under strict quarantine standards. They’re then given potential treatment medicines from major biopharma companies, including Pfizer.

The studies are incredibly valuable for Hvivo’s clients because they create cost-effective data much faster than other testing methods.

Rapid growth

Poorly-understood illnesses like long Covid and other respiratory viruses loom large over the global population.

And since 2020 the number of pharma companies testing vaccines and antivirals has soared. This is creating booming demand for Hvivo’s services.

Analysts see its bottom line improving from a £770,000 net loss in 2022 to a £7.54m profit in 2023. That’s the predicted 948% earnings increase I mentioned earlier. The company has also this year increased its profit margins from under 13% to 19%, and upped its revenue guidance.

Adding to this year’s record £78m order book is a £6.8m contract signed in February, followed by a £13.1m contract win in July.

Results released in September showed profit for the first half of the year up 126% to £5.2m. Net cash has also doubled to £31.3m (around 4.6p per share) in the last 12 months. Analysts have upgraded their earnings estimates for the next two years by 62% and 46%, respectively.

Risk and rewards

A quick word on risks though. Hvivo is listed on the UK’s AIM market. AIM shares are generally less liquid — that is, there are fewer buyers and sellers — than companies on the FTSE 100 or FTSE 250.

The other main risk (as with all growth stocks) is that expectations might not meet reality. That 948% increase could fall short, for instance, putting off new investors. For me, this is a calculated risk. I’ve taken into account what I think is a realistic assessment of the company’s mis-steps and successes to date.

Additionally, testing infectious and respiratory diseases on human volunteers remains a controversial practice.

Yet in my opinion, the risk is mitigated by Hvivo’s track record in running successful studies, along with having on-site immunology and virology laboratories.

Pharma karma

Hvivo is a picks and shovels play for my investment portfolio. Instead of bottomless R&D spending on creating vaccines or treatments? Hvivo only helps to test those medicines, and is paid handsomely for doing so.

Back in 2020, I wrote for The Motley Fool that I thought Hvivo shares could double my money.

They have — and more.

And with these analyst upgrades, I see even better growth ahead. So I’m doubling down again on Hvivo.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tom Rodgers has positions in Hvivo Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

2 recession-resistant UK stocks I’d buy and hold for a decade!

Our writer details two UK stocks she believes could still continue to perform well in a recession and not feel…

Read more »

Back view of blue NIO EP9 electric vehicle
Investing Articles

Down 31% this year! Is now the moment to buy NIO stock?

NIO stock has moved sharply downwards in the past couple of months. Christopher Ruane likes the business potential -- but…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 dividend stocks I reckon could grow payouts for years to come!

This Fool is looking for dividend stocks and explains why these two picks could be primed to grow their payouts…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Should I buy, sell, or hold my Rolls-Royce shares at £3.50?

This Fool considers what he should do with his Rolls-Royce shares following the FTSE 100 company's excellent full-year results last…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

With a spare £280, here’s how I’d start buying shares this March

Our writer reflects on what he has learnt on the stock market to explain how he would start buying shares…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Are these expensive FTSE 100 stocks actually brilliant bargains?

Paul Summers takes a closer look at two FTSE 100 stocks that could recover strongly in time, despite already carrying…

Read more »

Investing Articles

What might the recent Aviva share price performance tell me as an investor?

Christopher Ruane looks at how the Aviva share price has performed over the past 12 months and considers whether he…

Read more »

Investing Articles

Down by a quarter, is the BT share price a steal?

The BT share price has more than halved in the past five years. What is holding it down -- and…

Read more »